EGFR and non-small cell lung carcinoma: Our report, together with the clinical outcome of a patient from other centers, suggests that the combination of the third-generation EGFR-TKIs and pyrotinib has the potential to achieve long-term survival in EGFR-mutant/HER2-amplified NSCLC patients.